Three-drug combination prolongs survival in men with metastatic, hormone-sensitive prostate cancer
A phase 3 trial demonstrates multiple benefits of adding the androgen-receptor inhibitor darolutamide to standard therapy.
Contact Information
New Patients
If you have not previously seen a doctor within the Mass General Brigham Network:
Step 1: Obtain a medical record number (MRN).
Call the Mass General Registration & Referral Center to register as a patient and obtain an MRN: 866-211-6588.
Step 2: Call the Cancer Center new patient appointment line: 617-726-5130.
The schedulers can assist you in making the first available appointment with the appropriate physician. To help your call go smoothly, please have ready your:
Existing Patients
Call the Genitourinary Center scheduling line: 617-724-5197. They will connect you with your treatment team.
Support the Center Genitourinary Cancers
With your support, the team at the Claire and John Bertucci Center for Genitourinary Cancers is able maintain their commitment to quality patient care and advancing discoveries. Make a gift.
The Claire & John Bertucci Center for Genitourinary Cancers is one of the largest and most experienced centers in New England for the diagnosis and treatment of prostate cancer. Many of the diagnostic and therapeutic approaches available here are offered at only a few centers nationwide.
Our unique approaches to prostate cancer treatment include:
New patients are generally seen within a week of referral. We will work with you to develop a treatment plan that balances potential treatment side effects and benefits. We will continue to monitor your care and communicate regularly with you and your referring physician about your progress.
At your first appointment, you will meet the genitourinary cancer specialists who will be involved in your care, including:
In addition, you may also see:
Exact diagnosis and staging are critical to defining the appropriate treatment for your cancer, including establishing whether you are a candidate for active surveillance. Your team will include sub-specialized pathologists, who work exclusively on analyzing genitourinary tumors, and whose training and experience help ensure your treatment plan is based on a precise diagnosis. Our pathologists perform a Gleason score analysis of every prostate tumor to assess the likelihood of tumor spread.
In addition to using the standard imaging techniques, we are conducting clinical trials on the use of novel techniques to diagnose and stage prostate cancer.
These include:
Studies have shown patients do better when they are treated in a facility that cares for a high number of patients with the same form of cancer; we perform a large number of prostate cancer diagnostic and treatment procedures annually.
In addition to being skilled at conventional surgery, our genitourinary cancer surgeons are at the forefront of developing minimally invasive approaches for the treatment of prostate cancer, including both laparoscopic and robotic prostatectomy.Depending on the size of your prostate and the location of your cancer, you may receive internal radiation (brachytherapy) or external radiation. External radiation is delivered using advanced 3-dimensional (3-D) or intensity modulated (IMRT) radiation techniques. The prostate is targeted using daily imaging to precisely direct the radiation beam. As one of only a few centers nationwide offering proton radiation, we are working to understand its correct place in the treatment of prostate cancer.
Learn more about radiation therapy.
Clinical trials are research studies of new drugs, new combinations of drugs or already approved drugs being studied to treat patients in new/different ways. They may include new drug doses or new ways (schedules) to give the drugs. Clinical trials are run under strict guidelines. Their purpose is to help find out whether new cancer treatments are safe and effective or better than the standard (current) treatment. At Mass General Cancer Center, there are several clinical trials open for the treatment of prostate cancer that use the latest in cancer treatments.
Cancer is increasingly becoming a disease in which the genetic makeup of each individual cancer drives therapy. The Center for Genitourinary Cancers also has access to clinical trials involving these targeted therapy approaches.
Find listings of our current Clinical Trials for Prostate Cancer.
The prostate is a small, round gland located behind the pubic bone and in front of the rectum. Cancer that begins in the tissues of the prostate is called prostate cancer.
We help to identify families that may have a hereditary predisposition to prostate cancer.
Learn more about Mass General's Department of Urology.
Learn about the Genitourinary Program in the Dept of Radiation Oncology.
Learn more about the Center for Genitourinary Cancers.
A checklist of items to bring with you for your first visit and helpful information.
We offer a variety of education and support resources to help you and your family.
We offer a wide range of integrative therapies, workshops and support groups.
Mass General has the only proton therapy site in all of New England, with two proton therapy centers.
This helped lead to new knowledge and breakthrough therapies.
A phase 3 trial demonstrates multiple benefits of adding the androgen-receptor inhibitor darolutamide to standard therapy.
Walter Richard Ristow was 71 years old when he was diagnosed with prostate cancer.
Contact us to make an appointment or to learn more about our programs.